Connect. Influence. Grow.

Edgardo Hernandez (he/him/his) is executive vice president at Eli Lilly and Company and president of manufacturing operations.

Ed served as senior vice president of global parenteral drug product, delivery devices and regional manufacturing from 2018 until 2021. In this role, he was responsible for global parenteral manufacturing, emerging markets manufacturing, drug-product contract manufacturing, packaging, and distribution operations. Ed provided oversight for manufacturing sites in 12 countries across North America, South America, Europe, and Asia; that manufacture the final parenteral product (non-oral) formulations of Lilly medicines.

Previously, Ed was vice president of Fegersheim Operations for Lilly’s manufacturing site located in France. Before that, he served as site head for two other Lilly manufacturing sites: Indianapolis Active Pharmaceutical Ingredient manufacturing from 2014 until 2016, and PR06 in Puerto Rico from 2012 until 2014. Ed joined Lilly in 2005 as an engineering services leader for Lilly del Caribe in Puerto Rico, after working for several years in positions for Pfizer and Pharmacia.

Ed is a native of Puerto Rico and holds bachelor’s and master’s degrees in chemical engineering from the University of Puerto Rico and North Carolina State University, respectively.

Brendan O’Callaghan leads Sanofi’s Manufacturing and Supply organization, a global network of close to 40 internal manufacturing sites, supported by a network of strategic external supply partners. Sanofi’s ambition is to build an Industry leading manufacturing and supply chain capability, based on a future-ready organization and network that will ensure the flawless launch of Sanofi’s rich and diverse late-stage pipeline and the continued, reliable supply of essential, high-quality, affordable and sustainable medicines and vaccines for patients, worldwide. Sanofi will leverage the latest in scientific, digital, technology and workforce solutions to achieve this ambition.

Brendan joined Sanofi in 2015 as Global Head of Biologics, later taking leadership of the integrated Manufacturing and Supply network supporting our Specialty Care portfolio, prior to taking on his current responsibilities in September 2021. He has played a key role in enabling Sanofi’s transformation to a fully integrated BioPharma company and advancing the modernization and digital transformation of our manufacturing teams and network, building capabilities and capacities to support Sanofi’s growth in Biologics, Vaccines and Small Molecule Manufacturing, as highlighted by continued investments into state of the art, digitally advanced and future ready facilities such as the 2020 ISPE Facility of the Year award winning site in Framingham, MA and Sanofi’s agile and industry leading Modulus platforms in Neuville (FR) and Singapore.

Prior to Sanofi, Brendan worked with Merck / MSD, Mallinckrodt and Schering-Plough, where he led Tech Ops organizations of increasing scope and responsibility, across a variety of site and global leadership roles.

Brendan graduated in Chemical Engineering from the University College of Dublin, where he currently serves as an honorary adjunct Professor of Chemical and Biochemical Engineering.

He is married with four sons. A keen sports enthusiast, Brendan is a UEFA qualified soccer coach.

Sanat Chattopadhyay is responsible for the company’s (approx.  $64 billion revenue) worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products. Merck is known as MSD outside of the U.S. and Canada.

Sanat joined Merck in 2009 as Senior Vice President of Global Vaccines & Sterile Manufacturing Operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its Vaccine business. Under Sanat’s leadership, Merck is currently executing a significant expansion of its biologics and vaccines manufacturing capacity with planned capital investments of more than $20 billion from 2020 through the end of 2024, to reach more patients around the globe.

Before joining Merck, he served as Senior Vice President, Technical Operations & Product Supply, for Wyeth Pharmaceuticals. Previously, he worked at Aventis and its predecessor companies as Senior Vice President, Industrial Operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific. Sanat started his career with Hoechst Pharmaceuticals in 1983 and worked in many senior leadership assignments.

Sanat is a graduate in Chemical Engineering and holds a post-graduate degree in Industrial Engineering from India.

Outside of Merck, Sanat is a member of the Board of Directors of Ashland Inc.